載入中
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
前收盤價
US$3.63
−US$0.23 · -5.96%
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
17
估值過高
情緒
42
多空交錯
風險
74
高風險
動能
33
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
日內區間
目前US$3.63
52週區間
目前US$3.63
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 490.4萬 USD | 517.4萬 USD | 452.9萬 USD | 550.8萬 USD | 447.4萬 USD |
| 銷貨成本 | 153.1萬 USD | 3442.6萬 USD | 97.2萬 USD | 3501.7萬 USD | 2001.5萬 USD |
| 毛利 | 337.3萬 USD | −2925.2萬 USD | 355.7萬 USD | −2950.9萬 USD | −1554.1萬 USD |
| 研究與開發 | 2371.7萬 USD | 3442.6萬 USD | 3377萬 USD | 3501.7萬 USD | 2001.5萬 USD |
| 銷售、一般及管理費用 | 1240.9萬 USD | 1318.4萬 USD | 1067.7萬 USD | 743.7萬 USD | 828.1萬 USD |
| 營業費用 | 3459.5萬 USD | 1318.4萬 USD | 4444.7萬 USD | 743.7萬 USD | 828.1萬 USD |
| 利息收入 | 38.8萬 USD | 69.7萬 USD | 17.9萬 USD | 2.9萬 USD | 5000 USD |
| 利息支出 | 1659萬 USD | 1074.2萬 USD | 262.6萬 USD | 2.9萬 USD | 6.4萬 USD |
| 折舊和攤銷 | 153.1萬 USD | 132.5萬 USD | 97.2萬 USD | 89.2萬 USD | 116.9萬 USD |
| 營業利益 | −3122.2萬 USD | −4243.6萬 USD | −4089萬 USD | −3694.6萬 USD | −2382.2萬 USD |
| 淨利 | −1.74億 USD | −1891.6萬 USD | −6904.5萬 USD | −3691.7萬 USD | −2315.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$15.00
上漲空間 313.22%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
